The Amendment Act provides for amendments to the Narcotic Drugs Act 1967 to support an innovative Australian medicinal cannabis industry for the benefit of Australian patients.
On 2 December 2020, Australia voted at the Commission on Narcotic Drugs on six recommendations concerning the scheduling of cannabis and cannabis related substances
From 1 November 2020, subject to formal approval from the Federal Executive Council, cost recovery arrangements will be extended to cannabis-related manufacture licences and permits under the Medicinal Cannabis Scheme.